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Dyspepsia is a constellation of symptoms referable to the gas-troduodenal region of the upper gastrointestinal tract. Functional dyspep-sia, a relapsing and remitting disorder, is the most common cause of these 
symptoms. The current standard for the diagnosis of functional dyspepsia is the 
Rome III criteria, developed by the Rome III Committees, a multinational group 
of experts in the field, first convened in 1990, that meets regularly to review and 
revise the diagnostic criteria for all functional gastrointestinal disorders.
The Rome III criteria for functional dyspepsia consist of a sensation of pain or 
burning in the epigastrium, early satiety (inability to finish a normal-sized meal), 
fullness during or after a meal, or a combination of these symptoms (Table S1 in 
the Supplementary Appendix, available with the full text of this article at NEJM.org). 
Symptoms must be chronic, occurring at least weekly and over a period of at least 
6 months, in the absence of an organic explanation.1 The global prevalence of 
functional dyspepsia in the community according to this definition is between 5% 
and 11%.2
Up to 40% of persons who have functional dyspepsia consult a physician,3 and 
the condition negatively affects attendance and productivity in the workplace.4 
Functional dyspepsia has substantial financial implications for patients, health 
care organizations, and society as a whole; costs associated with the condition in 
the United States in 2009 were in excess of $18 billion.5 It is therefore important 
that physicians be able to recognize functional dyspepsia, use investigations and 
diagnostic tests judiciously, and recommend effective treatments, in order to 
minimize the potential adverse social and economic effects of the condition.
Di agnosis of Func tiona l Dyspepsi a
Symptoms do not reliably distinguish between organic and functional forms of the 
disease,6,7 so the challenge for the physician evaluating a patient with dyspepsia 
lies in discriminating between functional dyspepsia and organic conditions of the 
stomach or duodenum that may provoke similar symptoms (Table 1). In most 
cases, the cause can be clarified by means of upper gastrointestinal endoscopy, a 
test that generally shows that less than 10% of patients with dyspepsia have a 
peptic ulcer, less than 1% have gastroesophageal cancer, and more than 70% have 
functional dyspepsia.8 Celiac disease is the great mimic of many gastrointestinal 
disorders, but its frequency is not significantly increased among persons who re-
port dyspepsia.9 The patient’s medication history should be reviewed, but medica-
tion is not usually implicated in causing the dyspepsia.10
Given that upper gastrointestinal endoscopy is associated with a relatively low 
rate of identification of organic disease, it is neither desirable nor realistic to per-
form this test in all patients with dyspepsia. A primary care–based study showed 
that the cost of detecting each case of upper gastrointestinal cancer among patients 
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with dyspepsia was more than $80,000,11 which 
provides support for a selective approach. Guide-
lines recommend that patients with dyspepsia 
who report so-called alarm symptoms (Table 2), 
which may indicate an underlying gastroesopha-
geal cancer, be referred urgently for upper gastro-
intestinal endoscopy12; however, only a small per-
centage of patients who undergo this test have 
such a cancer, which indicates that alarm symp-
toms have only modest predictive capability.13
For patients with simple dyspepsia who do 
not have alarm symptoms, in whom the likeliest 
diagnosis is functional dyspepsia, the require-
ment for any further diagnostic testing depends 
on the background prevalence of Helicobacter pylori 
infection. In populations in which the prevalence 
of infection is at least 10%, noninvasive testing 
for H. pylori, with either carbon-13–labeled urea 
breath testing or stool antigen testing, is recom-
mended.12 In practice, however, because it is 
unlikely that the physician will be aware of the 
local prevalence of H. pylori, it is reasonable to 
use one of these tests as a first-line strategy, 
given that the testing is neither invasive nor pro-
hibitively expensive.
Functional dyspepsia may be confused with 
other gastrointestinal conditions outside the gas-
troduodenal region, including other functional 
disorders.14 In the past 20 years, there has been 
a concerted effort to standardize the definitions 
of functional dyspepsia, in part to minimize the 
likelihood of overlap with other functional gas-
trointestinal disorders. For the most part, this 
goal has been achieved by excluding from the 
definition of functional dyspepsia persons with 
symptoms suggestive of gastroesophageal reflux 
disease (GERD), such as retrosternal burning 
pain, regurgitation of acid into the mouth, or the 
irritable bowel syndrome, which is characterized 
by lower abdominal pain or discomfort associ-
ated with a change in stool form or frequency.1 
Despite this effort, in one study, more than 50% 
of the patients who met the criteria for func-
tional dyspepsia and who had normal 48-hour 
pH studies reported heartburn and regurgita-
tion, which were the predominant symptoms in 
30% of these patients.15 Common underlying 
mechanisms, such as failure of the gastric fundus 
to relax properly, may account for such symp-
toms in patients with overlapping functional 
dyspepsia and heartburn.16 In a factor-analysis 
study, the presence of lower gastrointestinal 
symptoms, such as diarrhea and constipation, 
increased the ability of physicians to discrimi-
nate between people with functional dyspepsia 
and those without it.17
There is also overlap between symptoms of 
functional dyspepsia and those of gastroparesis. 
More than one in four patients with functional 
dyspepsia have evidence of delayed gastric empty-
ing,18 and in one study 86% of the patients with 
gastroparesis met the criteria for functional 
dyspepsia,19 which suggests that these condi-
tions share similar pathophysiological features; 
the degree of overlap of symptoms also means 
that the capacity of diagnostic tests such as gas-
tric scintigraphy to discriminate between func-
tional dyspepsia and gastroparesis is limited.20 
The usefulness of ultrasonography in detecting 
relevant organic pancreatobiliary disease in pa-
Functional dyspepsia
Peptic ulcer disease and infection with Helicobacter pylori
Gastroesophageal cancer
Gastroparesis
Gallstones, sphincter of Oddi dysfunction, biliary dyskinesia, or gallbladder 
cancer
Drugs (e.g., nonsteroidal antiinflammatory drugs, iron, calcium antagonists, 
angiotensin-converting–enzyme inhibitors, methylxanthines, and gluco-
corticoids)
Chronic pancreatitis or pancreatic cancer
Parasites (e.g., Giardia lamblia, strongyloides, and anisakis)
Hepatocellular carcinoma
Chronic mesenteric ischemia
Crohn’s disease
Infiltrative diseases (e.g., eosinophilic gastroenteritis and sarcoidosis)
Table 1. Possible Underlying Causes of Symptoms of Dyspepsia.
Age >55 yr with new-onset dyspepsia*
Evidence of overt gastrointestinal bleeding including melena or hematemesis
Dysphagia, especially if progressive, or odynophagia
Persistent vomiting
Unintentional weight loss
Family history of gastric or esophageal cancer
Palpable abdominal or epigastric mass or abnormal adenopathy
Evidence of iron-deficiency anemia after blood testing
*  In regions with a high background prevalence rate of gastric cancer, such as 
Southeast Asia, a lower age threshold should be considered.
Table 2. Alarm Symptoms of an Underlying Upper Gastrointestinal Cancer.
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tients with dyspepsia who have normal results 
on upper gastrointestinal endoscopy was less 
than 5% in one primary care–based study.21
 Cl a ssific ation of Func tiona l 
Dyspepsi a
In the past 10 years, the terminology used to 
describe functional dyspepsia has changed, 
moving away from grouping patients according 
to the predominant reported symptom as having 
ulcer-like, reflux-like, or dysmotility-like func-
tional dyspepsia and instead describing them as 
having one of two newly defined syndromes, the 
epigastric pain syndrome and the postprandial 
distress syndrome. The epigastric pain syndrome 
consists of intermittent pain or burning in the 
epigastrium, occurring at least once per week, 
and the postprandial distress syndrome is 
marked by the occurrence at least several times 
per week of bothersome postprandial fullness 
occurring after normal-sized meals or by early 
satiety that prevents the person from finishing 
a regular meal (Table S1 in the Supplementary 
Appendix).1
These two syndromes were proposed because 
as many as 80% of persons with dyspepsia re-
port that their symptoms are aggravated by the 
ingestion of a meal.22 The definitions were also 
based on factor analysis that showed the group-
ing of dyspeptic symptoms into three or four 
clusters,23,24 with the epigastric pain syndrome 
and the postprandial distress syndrome appear-
ing consistently in several different studies. Sub-
sequent community-based cross-sectional sur-
veys, which showed good separation between 
these two subgroups, support this approach.25
Studies in referral populations are less convinc-
ing, however, with a greater degree of overlap 
evident between the epigastric pain syndrome 
and the postprandial distress syndrome (Fig. 1).7,26
The rationale for assigning patients into these 
two syndrome subtypes in the clinic is that the 
classification may help guide therapy.
 Pathoph ysiol o gic a l Fe at ur es 
of Func tiona l Dyspepsi a
Psychological distress, particularly anxiety, is 
associated with functional dyspepsia and may 
precede the onset of the disorder in some per-
sons.27 In others, the gut symptoms occur before 
the onset of anxiety, which suggests that a gut-
driven brain disorder may explain some cases.28
Central pain processing may be abnormal in 
persons with functional dyspepsia,29 although 
whether it is caused by gut disturbances or is a 
primary symptom is uncertain.30 Genetic factors 
have also been implicated in functional dyspep-
sia, but the associations remain weak.31
Functional dyspepsia has conventionally been 
attributed to a disturbance of gastric physiologic 
factors, such as slow gastric emptying, failure of 
the gastric fundus to relax after a meal (fundic 
disaccommodation, which is a vagal reflex), or 
gastric hypersensitivity with distention of the 
stomach.32 Some patients with functional dys-
pepsia have none of these abnormalities, and 
any link with specific symptoms is unconvinc-
ing, except possibly for the inability to finish a 
normal meal and fundic failure.18,22 Gastric ac-
commodation failure is also linked to transient 
Figure 1. Overlap between Subcategories of Functional Dyspepsia 
in Community-Based and Referral Populations.
The Venn diagrams show the degree of overlap between patients with 
 functional dyspepsia who present with the postprandial distress syndrome 
and those who present with the epigastric pain syndrome. A total of 114 
patients with functional dyspepsia were included in a community-based 
study25 (Panel A), and 482 were included in a study conducted in a referral 
population7 (Panel B).
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relaxations of the lower esophageal sphincter 
that occur in GERD and may, in part, explain 
the overlap of GERD with functional dyspepsia.16 
Duodenal hypersensitivity to acid or distention 
has also been reported in patients with func-
tional dyspepsia.33
Infections may cause functional dyspepsia, 
but Koch’s postulates have not yet been fulfilled 
for any microbe. The occurrence of a postinfec-
tious irritable bowel syndrome is well estab-
lished; however, gastroenteritis can also lead to 
functional dyspepsia or to a persistent combina-
tion of functional dyspepsia and symptoms of 
the irritable bowel syndrome. Salmonella, Esche-
richia coli O157, Campylobacter jejuni, Giardia lamblia, 
and norovirus may induce functional dyspepsia; 
risk factors include genetic factors and smok-
ing.34 It is conceivable that functional dyspepsia 
arises when the proximal small intestine or 
stomach becomes inflamed after an enteric in-
fection, whereas the irritable bowel syndrome 
may arise from involvement of the distal small 
intestine or colon; if both the proximal and dis-
tal small intestine are inflamed, an overlap 
syndrome (the irritable bowel syndrome and 
functional dyspepsia) may be likely,35 although 
this hypothesis needs formal testing.
Duodenal inflammation has been observed in 
up to 40% of patients with functional dyspepsia, 
particularly subtle duodenal eosinophilia with, 
in some cases, excess clusters of eosinophils and 
eosinophil degranulation adjacent to nerves 
(Fig. S1 in the Supplementary Appendix).36-38 
Duodenal eosinophilia has been linked to smok-
ing and to symptoms of early satiety and pain; 
barrier disruption and increased duodenal perme-
ability have been documented.36,39 In some cases, 
mast cells that can recruit eosinophils have also 
been observed in functional dyspepsia, but the 
patient population that was studied included 
patients with both functional dyspepsia and the 
irritable bowel syndrome.39 Further evidence link-
ing intestinal inflammation to functional dys-
pepsia is provided by the finding of enhanced 
small-bowel homing T lymphocytes that are 
positive for both α4β7 integrin and chemokine 
receptor 9 in patients with functional dyspepsia 
— a finding that has been significantly associ-
ated with the release of cytokines (including 
tumor necrosis factor α), a greater severity of 
symptoms, and delayed gastric emptying,40 thus 
implicating the duodenum in gastric disorders.41
Together, these findings suggest that some 
patients with functional dyspepsia may have 
an organic mechanism for their symptoms. An-
other likely infectious cause is H. pylori. Although 
H. pylori infection is usually asymptomatic, in a 
small subgroup of patients with functional dys-
pepsia the eradication of infection leads to the 
long-term resolution of symptoms.42 The role of 
other components of the microbiome in func-
tional dyspepsia is unknown.43
Functional dyspepsia is most often a meal-
induced syndrome.22,44 A high-fat meal, for exam-
ple, can alter gastroduodenal physiology by means 
of altered gut-hormone responses,45 including by 
raising cholecystokinin levels.46 Food intolerance 
or allergy may play a direct role in functional 
dyspepsia, but this possibility has been poorly 
studied.47
An overarching disease model postulates that, 
in genetically predisposed persons, an allergen 
or infection leads to antigen presentation, bar-
rier disruption, immune activation, and a type 2 
helper T-cell response in functional dyspepsia, 
in which eosinophils are recruited that degranu-
late in some patients (Fig. 2).48 In some patients, 
this process can lead to tissue injury and symp-
toms, whereas in others eosinophils may be 
protective and promote healing. An inflamed 
duodenum may be sensitive to acid and induce 
reflex responses and cytokine release that alter 
gastroduodenal function and result in meal- 
related symptoms. If this hypothesis is correct, 
then some patients with functional dyspepsia 
may have a response to therapy targeted at im-
mune activation, but this remains to be estab-
lished; however, preliminary data in children 
suggest that montelukast, a leukotriene-receptor 
antagonist, reduces symptoms.49
Tr e atmen t of Func tiona l 
Dyspepsi a
Placebo or Reassurance
The rate of response to placebo in trials involv-
ing patients with functional dyspepsia is 30% to 
40%,42,50 but factors that influence this rate have 
not been analyzed systematically. A randomized 
clinical trial that compared placebo with no 
treatment in patients with the irritable bowel 
syndrome51 showed a significantly greater likeli-
hood of adequate relief of symptoms with pla-
cebo, but we are unaware of any similar trials 
involving patients with functional dyspepsia. 
There have also been no randomized trials of 
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reassurance as a treatment strategy in patients 
with functional dyspepsia, although this ap-
proach is often used by physicians. It should be 
pointed out that any reassurance derived from 
investigations that have ruled out organic dis-
ease is minimal.52
 H. pylori Eradication Therapy
Although 5% of the cases of dyspepsia in the 
community are attributable to infection with 
H. pylori,53 the effect of eradication therapy on 
the symptoms of functional dyspepsia is mod-
est. In a meta-analysis of 17 randomized trials, 
Figure 2. An Overarching Disease Model of Functional Dyspepsia.
In the presence of a background genetic disposition, a type 2 helper T (Th2)–cell response may be activated in the 
duodenum, possibly by allergens or pathogens, which cross through the gut epithelium. Resident and recruited eosin-
ophils may be activated by eotaxin, which is expressed constitutively in the lamina propria, and act as antigen-present-
ing cells to Th2 lymphocytes, which in turn express interleukin-5. This process can lead to eosinophil degranulation 
that impinges on nerve fibers, which may then fire, inducing muscle contraction or pain. Duodenal feedback to the 
stomach by means of interleukin-4 and interleukin-13, also expressed by Th2 cells, may promote immunoglobulin 
class switching to proallergic IgE antibody expression by B cells, further recruiting eosinophils and leading to de-
granulation with increased epithelial permeability. The cytokines tumor necrosis factor α (TNF-α), interleukin-10, 
and interleukin-1β can then be released into the blood and invoke an anxiety or stress response, which in turn may 
lead to disordered motility and visceral hypersensitivity in the stomach and duodenum. Gut-homing T cells may 
also increase in number and produce excess inflammatory cytokines that could then delay gastric emptying. APC 
denotes antigen-presenting cell.
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involving 3566 patients, the relative risk of per-
sistent symptoms was 0.90 (95% confidence in-
terval [CI], 0.86 to 0.94), with a number needed 
to treat of 15.42 Nevertheless, economic model-
ing that was based on these data suggests that 
eradication therapy is a cost-effective strategy 
for managing functional dyspepsia.54 Evidence 
continues to accumulate that such therapy is 
beneficial.55 A trial assessing the effect of eradi-
cation therapy according to individual symptoms 
reported by the patient56 showed a significant 
effect on epigastric pain and burning but not on 
early satiety or postprandial fullness. These data 
suggest that the benefit of eradication therapy 
may be more pronounced in patients with the 
epigastric pain syndrome than in others.
Acid-Suppression Therapy
Despite evidence of impaired duodenal clearance 
of gastric acid and duodenal hypersensitivity to 
infused gastric acid in persons with functional 
dyspepsia,33 the efficacy of acid-suppressive drugs 
such as proton-pump inhibitors (PPIs) or histamine 
H2-receptor antagonists is modest. A Cochrane 
meta-analysis of 10 randomized trials of PPIs, 
involving 3347 patients, reported a relative risk 
of persistent symptoms of 0.87 (95% CI, 0.80 to 
0.96) and a number needed to treat of 10.50 For 
histamine H2-receptor antagonists, the effect 
was more pronounced than with PPIs (relative 
risk, 0.77; 95% CI, 0.65 to 0.92; number needed 
to treat, 7), but the quality of the trials was 
lower. The majority of these trials were com-
pleted before the Rome III classification of func-
tional dyspepsia, and subgroup analyses were 
therefore conducted according to the predomi-
nant symptoms reported by the patients rather 
than according to whether the patients had the 
epigastric pain syndrome or the postprandial 
distress syndrome.
The meta-analysis showed that PPIs were ef-
fective in patients reporting reflux-like or ulcer-
like functional dyspepsia but not in patients with 
dysmotility-like functional dyspepsia.12 However, 
a recent trial conducted in Japan that confirmed 
the efficacy of the PPI rabeprazole in patients 
with functional dyspepsia did not show any dif-
ference in the effect of treatment according to 
whether patients met the criteria for the epigas-
tric pain syndrome or the postprandial distress 
syndrome.57 A trial of acid suppression seems to 
be a worthwhile strategy in most patients with 
functional dyspepsia, particularly in those who 
have negative results on H. pylori testing or in 
those with positive results on H. pylori testing in 
whom eradication therapy has not improved 
symptoms. Antacids, bismuth, and sucralfate are 
not efficacious in functional dyspepsia.12
Prokinetic Agents
A substantial proportion of patients with func-
tional dyspepsia have abnormalities in gastric 
motility and fundal accommodation.58 Existing 
prokinetic agents, including cisapride, domperi-
done, and itopride, have all been tested in func-
tional dyspepsia and have been shown to be more 
effective than placebo in a meta-analysis of 24 
randomized trials.50 Cisapride was withdrawn 
because of its increased risk of adverse cardiac 
events, including sudden death due to a pro-
longed QT interval, and itopride was no more 
effective than placebo in two large trials pub-
lished after this meta-analysis.59 Metoclopramide 
is not recommended routinely because of its un-
certain efficacy and side effects (including irre-
versible tardive dyskinesia), and the prescription 
of domperidone in the United States requires 
an Investigational New Drug application to the 
Food and Drug Administration.60
Partly as a result of the lack of efficacy of 
these drugs, new agents have been developed 
and tested in recent years. Acotiamide is an acetyl-
cholinesterase inhibitor that accelerates gastric 
emptying and enhances gastric accommodation.61 
In a double-blind, placebo-controlled trial in-
volving 897 patients with functional dyspepsia 
in Japan, symptoms improved in 52% of those 
assigned to active therapy, as compared with 
35% of those assigned to placebo (P<0.001).62 
When the effect of acotiamide on individual 
dyspeptic symptoms was studied, significant 
improvements were identified in postprandial 
fullness, upper abdominal bloating, and early 
satiety but not in upper abdominal pain or dis-
comfort. The drug has now been approved for 
the treatment of the postprandial distress syn-
drome in Japan, and phase 3 trials are ongoing 
in Western populations.
Drugs such as buspirone and tandospirone, 
which act on the 5-hydroxytryptamine-1A recep-
tor, leading to relaxation of the gastric fundus, 
have also been tested in functional dyspepsia. 
A randomized crossover trial of buspirone in 17 
patients with functional dyspepsia showed that 
the drug was effective in relaxing the gastric 
fundus and reduced bloating and postprandial 
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fullness.63 In a double-blind, placebo-controlled 
study involving 144 patients, the response rate 
after 4 weeks of treatment with tandospirone 
was 31.5%, as compared with 12.7% with placebo 
(P = 0.002).64
Antidepressants
Because of the potential role of the brain–gut 
axis and abnormal central pain processing in 
functional dyspepsia,29,30 antidepressants have 
been suggested as a second-line or third-line 
therapy for many years, but it is only in the past 
decade that their efficacy has been tested in 
large, rigorously designed clinical trials. A trial 
of venlafaxine in 160 patients with functional 
dyspepsia showed no benefit after 8 weeks of 
treatment (37% of the patients were symptom 
free with venlafaxine, as compared with 39% 
with placebo).65 In a placebo-controlled trial of 
sertraline in 193 patients in China, 28% of the 
patients randomly assigned to the active drug 
had complete relief of their symptoms, as com-
pared with 28% of those assigned to placebo.66
Mirtazapine has also been assessed in 34 
patients with functional dyspepsia and weight 
loss67; significant improvements were seen in 
early satiety and quality of life at 8 weeks in the 
patients assigned to mirtazapine, as compared 
with those assigned to placebo. More recently, in 
a large North American multicenter trial, 292 
patients with functional dyspepsia were assigned 
to amitriptyline, escitalopram, or placebo.68 The 
rate of response after 10 weeks was 53% with 
amitriptyline, 38% with escitalopram, and 40% 
with placebo (P = 0.05 for the three-way com-
parison). Taken together, these data suggest that 
tricyclic antidepressants, such as amitriptyline, 
should be preferred over selective serotonin-
reuptake inhibitors or serotonin–norepinephrine 
reuptake inhibitors for the treatment of func-
tional dyspepsia.
Psychological Therapy
The use of psychological therapy in functional 
dyspepsia remains an under-studied area. A Co-
chrane review published 10 years ago identified 
only four studies and highlighted the need for 
more research addressing this issue.69 Few studies 
have been published since this review, although 
a recent trial involving 158 patients with func-
tional dyspepsia in Spain randomly assigned 
participants to receive conventional medical treat-
ment or conventional medical treatment plus 
psychotherapy.70 There were significant improve-
ments in dyspepsia-related quality-of-life and 
symptom scores at 10 weeks with psychother-
apy, and these effects persisted for as long as 
6 months after the end of treatment. However, 
these data should be regarded as preliminary.
More studies will be required before the place 
of psychological therapy in the treatment of 
functional dyspepsia is known. That said, such 
treatment should probably be considered for 
patients who have not had any improvement in 
their symptoms with conventional medical ther-
apies, particularly in those with coexisting im-
pairment of mood.
Complementary and Alternative Therapy
Given the limited efficacy of the majority of 
conventional medical therapies, it is not surpris-
ing that up to 50% of patients with functional 
dyspepsia seek out other forms of treatment71; in 
one study, nearly 50% of the patients were will-
ing to accept a 12.7% risk of sudden death with 
a drug that offered a 99% chance of cure,72 in 
the hope of improving their symptoms and qual-
ity of life. However, consistent evidence of the 
efficacy of acupuncture, homeopathy, or probiot-
ics in functional dyspepsia is lacking.
Some patients may find herbal supplements, 
such as the nine-herb combination product 
iberogast (also known as STW5),73 beneficial, 
and STW5 has been observed to relax the gastric 
fundus.74 Capsaicin, a component of red pepper, 
was superior to placebo in terms of the reduc-
tion in symptom scores in one small trial,75 but 
more studies are needed before any definitive 
conclusions can be drawn. Disordered sleep is 
more common in patients with functional dys-
pepsia than in healthy controls without func-
tional dyspepsia, and it appears to be correlated 
with the severity of symptoms,76 but no interven-
tion studies have been performed.
Management of Functional Dyspepsia
All patients with functional dyspepsia should be 
offered a positive diagnosis after targeted inves-
tigation, reassurance that the disorder does not 
negatively affect survival,77 and an explanation of 
the probable origin of symptoms. Attention to 
stress reduction and lowering of anxiety is im-
portant, and dietary advice should be provided 
(e.g., ingestion of small, regular, low-fat meals 
and avoidance of foods that precipitate symp-
toms, if possible). However, there is no evidence 
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to support the screening of all patients with 
functional dyspepsia for anxiety or for treating 
those in whom it is present with an anxiolytic. 
A treatment algorithm is presented in Figure 3.
Management of Refractory Functional 
Dyspepsia
In patients whose symptoms do not respond to 
standard medical therapy, treatment is empiri-
cal. In our experience, histamine H2-receptor 
antagonists may help even if PPIs have failed. 
The combination of acid suppression with a pro-
kinetic agent appears to benefit some other pa-
tients. The combination of peripheral drug ther-
apy with psychological treatment is promising.70
If pain is the predominant symptom despite 
these strategies, the physician should consider 
other options, although these are empirical and 
not evidence-based.78 Approaches that may be 
helpful include adjusting the dose of a tricyclic 
antidepressant to the full antidepressant level, 
prescribing an antipsychotic drug such as levo-
Figure 3. Recommended Treatment Algorithm for Patients with a Provisional Diagnosis of Functional Dyspepsia.
This treatment algorithm can be applied in patients who present with epigastric pain or burning, early satiation, or postprandial fullness. 
In the case of treatment failure, the clinician should reevaluate and reconsider the diagnosis at each step by means of further investiga-
tions, such as upper gastrointestinal endoscopy if the procedure has not been performed within the past 5 years; ultrasonography of the 
abdomen, particularly if the patient has severe, intermittent episodes of pain; serologic testing for celiac disease; and gastric scintigra-
phy or carbon-13–labeled octanoic or spirulina (Arthrospira platensis) breath test to assess gastric emptying if the symptoms are severe 
or resistant to treatment or if the patient has vomiting and prominent weight loss. There are no data from randomized trials in support 
of using metoclopramide to treat patients with the postprandial distress syndrome; we suggest starting the drug at a low dose owing to 
the potential for cardiac and neurologic toxic effects. PPI denotes proton-pump inhibitor.
Epigastric pain or burning, early 
satiety, or postprandial fullness
Alarm symptoms 
present?
Urgent 
upper gastrointestinal 
endoscopy
Local H. pylori 
prevalence ≥10%?
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eradication therapy
Empirical acid suppres-
sion therapy for 4–8 wk
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Discharge and try
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No
No
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Treat relevant underlying 
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 acotiamide (where 
available), domperidone, 
or metoclopramide 
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Avoid opiates;
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sulpiride,79 or adding an anxiolytic (e.g., buspi-
rone) to a tricyclic antidepressant. The combina-
tion of an antidepressant with pregabalin or 
gabapentin is yet another option that appears to 
relieve pain. Opioids have no therapeutic role in 
the management of functional dyspepsia and 
should be avoided because of the risk of depen-
dence, the frequent failure of analgesia, and 
possibility of the narcotic bowel syndrome.80
Pro gnosis in Func tiona l 
Dyspepsi a
In most patients with functional dyspepsia, the 
natural history is chronic and fluctuating, with 
periods of time when the patient is asymptom-
atic followed by episodes of symptom relapse. 
Data from population-based studies suggest that, 
during extended follow-up, approximately 15 to 
20% of people with functional dyspepsia have 
persistent symptoms and 50% have resolution of 
symptoms; in the remaining 30 to 35% of pa-
tients symptoms will fluctuate and meet the 
criteria for another functional gastrointestinal 
disorder.81 Despite the chronic nature of func-
tional dyspepsia, there is no evidence to suggest 
that it is associated with decreased survival.77
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